Ruptured cerebral aneurysms lead to subarachnoid hemorrhage (SAH),that has a high morbidity
and mortality rate, the severity of which is predicted by the "Hunt-Hess grade" (HHG).
SAH leads to iron (Fe) and hemoglobin (Hb) accumulation in the brain, which is toxic for
neurons. Ferritin (iron reported in the brian) and iron overload leads to brain atrophy,
specifically in the mesial temporal lobe (hippocampus, impairing patients' cognition. It is
estimated that 50% of survivors have cognitive deficits.
Most of the survivors of SAH could not return to work. Iron chelation therapy has been
recently gaining ground as a therapeutic intervention in intraparenchymal hemorrhage and in
SAH. However, there has not been any study that assess the iron deposition in the brain and
the level of ferritin in the cerebrospinal fluid of SAH patients. The investigators propose
to conduct a randomized trial using Deferiprone (oral chelating agent, "De") + standard of
care vs standard of care in patient with SAH to:
1. assess the level of ferritin (Ft) in CSF (CSF withdrawn from ventriculostomy tube),
2. assess functional outcomes measured by the Montreal Cognitive Assessment (MoCA) score, a
score used to assess the level of dementia, mainly in Alzheimer disease patients.
3. quantify the the total iron deposition in the brain based on MRI